nach oben

Discover Oncology

Erschienen in:

01.08.2013 | Original Paper

CREB-Regulated Transcription Co-Activator Family Stimulates Promoter II-Driven Aromatase Expression in Preadipocytes

verfasst von: Nirukshi U. Samarajeewa, Maria M. Docanto, Evan R. Simpson, Kristy A. Brown

Erschienen in: Discover Oncology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

The dramatically increased prevalence of breast cancer after menopause is of great concern and is correlated with elevated local levels of estrogens. This is mainly due to an increase in aromatase expression driven by its proximal promoter II (PII). We have previously demonstrated that the CREB co-activator CRTC2 binds directly to PII and stimulates its activity via mechanisms involving LKB1-AMPK in response to prostaglandin E₂ (PGE₂). There are three members of the CRTC family (CRTC1-3) and this study aimed to characterize the role of other CRTCs in the activation of aromatase PII. The expression and subcellular localization of CRTCs were examined in preadipocytes using qPCR and immunofluorescence. Under basal conditions, CRTC1 expression was the lowest, whereas CRTC3 transcripts were present at higher levels. Basally, CRTC2 and CRTC3 were mainly cytoplasmic and PGE₂ caused their nuclear translocation. Reporter assays and chromatin immunoprecipitation (ChIP) were performed to assess the effect of CRTCs on PII activity and binding. Basal PII activity was significantly increased with all CRTCs. Forskolin (FSK)/phorbol 12-myristate 13-acetate (PMA), to mimic PGE₂, resulted in a further significant increase in PII activity with all CRTCs, with CRTC2 and CRTC3 having greater effects. This was consistent with ChIP data showing an increased binding of CRTCs to PII with FSK/PMA. Moreover, gene silencing of CRTC2 and CRTC3 significantly reduced the FSK/PMA-mediated stimulation of aromatase activity. Interestingly, CRTCs acted cooperatively with CREB1 to increase PII activity, and both CREs were found to be essential for the maximal induction of PII activity by CRTCs. Phosphorylation of CRTC2 at its AMPK target site, Ser 171, dictated its subcellular localization, and the activation of aromatase PII in preadipocytes. In conclusion, this study demonstrates that aromatase regulation in primary human breast preadipocytes involves more than one CRTC.

Simpson ER, Brown KA (2011) Obesity, aromatase and breast cancer. Expert Rev Endocrinol Metab 6(3):383–395CrossRef

Sofi M et al (2003) Role of CRE-binding protein (CREB) in aromatase expression in breast adipose. Breast Canc Res Treat 79(3):399–407CrossRef

Gonzalez GA, Montminy MR (1989) Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 59(4):675–680PubMedCrossRef

Roberts DL, Dive C, Renehan AG (2010) Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 61:301–316PubMedCrossRef

Harvie M, Hooper L, Howell AH (2003) Central obesity and breast cancer risk: a systematic review. Obes Rev 4(3):157–173PubMedCrossRef

Stoll BA (2002) Upper abdominal obesity, insulin resistance and breast cancer risk. Int J Obes Relat Metab Disord 26(6):747–753PubMedCrossRef

Subbaramaiah K et al (2012) Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2(4):356–365PubMedCrossRef

Zhang X et al (2005) Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci U S A 102(12):4459–4464PubMedCrossRef

Iourgenko V et al (2003) Identification of a family of cAMP response element-binding protein coactivators by genome-scale functional analysis in mammalian cells. Proc Natl Acad Sci U S A 100(21):12147–12152PubMedCrossRef

10.

Conkright MD et al (2003) TORCs: transducers of regulated CREB activity. Molecular Cell 12(2):413–423PubMedCrossRef

11.

Bittinger MA et al (2004) Activation of cAMP response element-mediated gene expression by regulated nuclear transport of TORC proteins. Curr Biol 14(23):2156–2161PubMedCrossRef

12.

Screaton RA et al (2004) The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector. Cell 119(1):61–74PubMedCrossRef

13.

Altarejos JY, Montminy M (2011) CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol 12(3):141–151PubMedCrossRef

14.

Katoh Y et al (2006) Silencing the constitutive active transcription factor CREB by the LKB1-SIK signaling cascade. FEBS J 273(12):2730–2748PubMedCrossRef

15.

Koo S-H et al (2005) The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437(7062):1109–1111PubMedCrossRef

16.

Mair W et al (2011) Lifespan extension induced by AMPK and calcineurin is mediated by CRTC-1 and CREB. Nature 470(7334):404–408PubMedCrossRef

17.

Brown KA et al (2009) Subcellular localization of cyclic AMP-responsive element binding protein-regulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women. Cancer Res 69(13):5392–5399PubMedCrossRef

18.

Michael MD et al (1995) Ad4BP/SF-1 regulates cyclic AMP-induced transcription from the proximal promoter (PII) of the human aromatase P450 (CYP19) gene in the ovary. J Biol Chem 270(22):13561–13566PubMedCrossRef

19.

Ackerman GE et al (1981) Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. J Clin Endocrinol Metab 53(2):412–417PubMedCrossRef

20.

Brown KA et al (2010) Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res Treat 123(2):591–596PubMedCrossRef

21.

Lephart ED, Simpson ER (1991) Assay of aromatase activity. Methods Enzymol 206:477–483PubMedCrossRef

22.

Wang Y et al (2010) Targeted disruption of the CREB coactivator Crtc2 increases insulin sensitivity. Proc Natl Acad Sci U S A 107(7):3087–3092PubMedCrossRef

23.

Xiao X et al (2010) Targeting CREB for cancer therapy: friend or foe. Curr Cancer Drug Targets 10(4):384–391PubMedCrossRef

24.

Chhabra A et al (2007) Expression of transcription factor CREB1 in human breast cancer and its correlation with prognosis. Oncol Rep 18(4):953–958PubMed

Titel: CREB-Regulated Transcription Co-Activator Family Stimulates Promoter II-Driven Aromatase Expression in Preadipocytes
verfasst von: Nirukshi U. Samarajeewa
Maria M. Docanto
Evan R. Simpson
Kristy A. Brown
Publikationsdatum: 01.08.2013
Verlag: Springer-Verlag
Erschienen in: Discover Oncology / Ausgabe 4/2013
Print ISSN: 1868-8497
Elektronische ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-013-0142-1

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

CREB-Regulated Transcription Co-Activator Family Stimulates Promoter II-Driven Aromatase Expression in Preadipocytes

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Protein Tyrosine Phosphatase 4A2 Expression Predicts Overall and Disease-Free Survival of Human Breast Cancer and Is Associated with Estrogen and Progestin Receptor Status

Translational Highlights

RNA Sequencing of MCF-7 Breast Cancer Cells Identifies Novel Estrogen-Responsive Genes with Functional Estrogen Receptor-Binding Sites in the Vicinity of Their Transcription Start Sites

Serum Vitamin D Metabolites in Colorectal Cancer Patients Receiving Cholecalciferol Supplementation: Correlation with Polymorphisms in the Vitamin D Genes

Occult Breast Tumor Reservoir: Biological Properties and Clinical Significance

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie